Plasma membrane SK2 channel activity regulates migration and chemosensitivity of high-grade serous ovarian cancer cells.
LPA
SK2 channel
Taxol®
cell migration
chemosensitivity
high-grade serous ovarian cancer
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
revised:
30
01
2024
received:
03
10
2023
accepted:
29
02
2024
medline:
14
3
2024
pubmed:
14
3
2024
entrez:
14
3
2024
Statut:
aheadofprint
Résumé
No data are currently available on the functional role of small conductance Ca
Identifiants
pubmed: 38480668
doi: 10.1002/1878-0261.13631
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Canceropôle Grand Ouest
Organisme : Conseil Régional du Centre-Val de Loire
Organisme : Institut National de la Santé et de la Recherche Médicale
Organisme : Ligue Contre le Cancer
Organisme : University of Tours
Informations de copyright
© 2024 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Lisio M-A, Fu L, Goyeneche A, Gao Z, Telleria C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20(4):952. https://doi.org/10.3390/ijms20040952
Pua TL, Wang F, Fishman DA. Roles of LPA in ovarian cancer development and progression. Future Oncol. 2009;5(10):1659-1673. https://doi.org/10.2217/fon.09.120
Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC, LaPolla JP, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(7):7.
Xu Y. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998;280(8):719-723. https://doi.org/10.1001/jama.280.8.719
Kim JH, Adelstein RS. LPA1-induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells. J Cell Physiol. 2011;226(11):2881-2893. https://doi.org/10.1002/jcp.22631
Park J, Jang J-H, Oh S, Kim M, Shin C, Jeong M, et al. LPA-induced migration of ovarian cancer cells requires activation of ERM proteins via LPA1 and LPA2. Cell Signal. 2018;44:138-147. https://doi.org/10.1016/j.cellsig.2018.01.007
Wang H, Liu W, Wei D, Hu K, Wu X, Yao Y. Effect of the LPA-mediated CXCL12-CXCR4 axis in the tumor proliferation, migration and invasion of ovarian cancer cell lines. Oncol Lett. 2014;7:1581-1585. https://doi.org/10.3892/ol.2014.1926
Falcetta FS, Lawrie TA, Medeiros LR, da Rosa MI, Edelweiss MI, Stein AT, et al. Laparoscopy versus laparotomy for FIGO stage I ovarian cancer. Cochrane Database Syst Rev. 2016;2022(1). https://doi.org/10.1002/14651858.CD005344.pub4
Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol. 1992;45(3):284-289. https://doi.org/10.1016/0090-8258(92)90305-3
Cancer statistics, 1980. CA Cancer J Clin. 1980;30(1):23-38. https://doi.org/10.3322/canjclin.30.1.23
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/10.3322/caac.21660
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284-296. https://doi.org/10.3322/caac.21456
Guéguinou M, Chantôme A, Fromont G, Bougnoux P, Vandier C, Potier-Cartereau M. KCa and Ca2+ channels: the complex thought. Biochim Biophys Acta. 2014;1843(10):2322-2333. https://doi.org/10.1016/j.bbamcr.2014.02.019
Chantôme A, Potier-Cartereau M, Clarysse L, Fromont G, Marionneau-Lambot S, Guéguinou M, et al. Pivotal role of the lipid raft SK3-Orai1 complex in human cancer cell migration and bone metastases. Cancer Res. 2013;73(15):4852-4861. https://doi.org/10.1158/0008-5472.CAN-12-4572
Guéguinou M, Harnois T, Crottes D, Uguen A, Deliot N, Gambade A, et al. SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline. Oncotarget. 2016;7(24):36168-36184. https://doi.org/10.18632/oncotarget.8786
Sun J, Liu Y, Baudry M, Bi X. SK2 channel regulation of neuronal excitability, synaptic transmission, and brain rhythmic activity in health and diseases. Biochim Biophys Acta Mol Cell Res. 2020;1867(12):118834. https://doi.org/10.1016/j.bbamcr.2020.118834
Honrath B, Matschke L, Meyer T, Magerhans L, Perocchi F, Ganjam GK, et al. SK2 channels regulate mitochondrial respiration and mitochondrial Ca2+ uptake. Cell Death Differ. 2017;24(5):761-773. https://doi.org/10.1038/cdd.2017.2
Ohtsuki G, Piochon C, Adelman JP, Hansel C. SK2 channel modulation contributes to compartment-specific dendritic plasticity in cerebellar Purkinje cells. Neuron. 2012;75(1):108-120. https://doi.org/10.1016/j.neuron.2012.05.025
Richter M, Vidovic N, Honrath B, Mahavadi P, Dodel R, Dolga AM, et al. Activation of SK2 channels preserves ER Ca2+ homeostasis and protects against ER stress-induced cell death. Cell Death Differ. 2016;23(5):814-827. https://doi.org/10.1038/cdd.2015.146
Zhang Z, Ledford HA, Park S, Wang W, Rafizadeh S, Kim HJ, et al. Distinct subcellular mechanisms for the enhancement of the surface membrane expression of SK2 channel by its interacting proteins, α-actinin2 and filamin a: regulation of membrane expression of SK2 channels. J Physiol. 2017;595(7):2271-2284. https://doi.org/10.1113/JP272942
Potier M, Joulin V, Roger S, Besson P, Jourdan M-L, LeGuennec J-Y, et al. Identification of SK3 channel as a new mediator of breast cancer cell migration. Mol Cancer Ther. 2006;5(11):2946-2953. https://doi.org/10.1158/1535-7163.MCT-06-0194
Rapetti-Mauss R, Nigri J, Berenguier C, Finetti P, Tubiana SS, Labrum B, et al. SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer. Gut. 2023;72(4):722-735. https://doi.org/10.1136/gutjnl-2021-326610
Targeting Kca3.1 channels in cancer. Cell Physiol Biochem. 2021;55(S3):131-144. https://doi.org/10.33594/000000374
Figiel B, Chantôme F, Pasqualin M, Domingo G, Bruyère P-C, Vandier F, et al. A novel calcium-mediated EMT pathway controlled by lipids: an opportunity for prostate cancer adjuvant therapy. Cancer. 2019;11(11):1814. https://doi.org/10.3390/cancers11111814
Mlayah-Bellalouna S, Aissaoui-Zid D, Chantome A, Jebali J, Souid S, Ayedi E, et al. Insights into the mechanisms governing P01 scorpion toxin effect against U87 glioblastoma cells oncogenesis. Front Pharmacol. 2023;14:1203247. https://doi.org/10.3389/fphar.2023.1203247
Tajima N, Schönherr K, Niedling S, Kaatz M, Kanno H, Schönherr R, et al. Ca2+−activated K+ channels in human melanoma cells are up-regulated by hypoxia involving hypoxia-inducible factor-1α and the von Hippel-Lindau protein: KCa channel regulation by hypoxia. J Physiol. 2006;571(2):349-359. https://doi.org/10.1113/jphysiol.2005.096818
Mpari B, Sreng L, Regaya I, Mourre C. Small-conductance Ca2+−activated K+ channels: heterogeneous affinity in rat brain structures and cognitive modulation by specific blockers. Eur J Pharmacol. 2008;589(1-3):140-148. https://doi.org/10.1016/j.ejphar.2008.05.019
Bery F, Cancel M, Guéguinou M, Potier-Cartereau M, Vandier C, Chantôme A, et al. Zeb1 and SK3 channel are up-regulated in castration-resistant prostate cancer and promote neuroendocrine differentiation. Cancer. 2021;13(12):2947. https://doi.org/10.3390/cancers13122947
Brouard T, Chantôme A. Two approaches for automatic nuclei cell counting in low resolution fluorescence images. In: Tavares JM, Jorge RM, editors. Computational Vision and Medical Image Processing: Recent Trends. Berlin: Springer; 2011. p. 311-326.
Chamlali M, Kouba S, Rodat-Despoix L, Todesca LM, Pethö Z, Schwab A, et al. Orai3 Calcium Channel regulates breast cancer cell migration through calcium-dependent and -independent mechanisms. Cells. 2021;10(12):3487. https://doi.org/10.3390/cells10123487
Potier M, Chantome A, Joulin V, Girault A, Roger S, Besson P, et al. The SK3/KCa2.3 potassium channel is a new cellular target for edelfosine: Edelfosine decreases SK3-mediated cell migration. Br J Pharmacol. 2011;162(2):464-479. https://doi.org/10.1111/j.1476-5381.2010.01044.x
Lánczky A, Győrffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res. 2021;23(7):e27633. https://doi.org/10.2196/27633
Győrffy B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. GeroScience. 2023;45(3):1889-1898. https://doi.org/10.1007/s11357-023-00742-4
Chantôme A, Potier-Cartereau M, Clarysse L, Fromont G, Marionneau-Lambot S, Guéguinou M, et al. Pivotal role of the lipid raft SK3-Orai1 complex in human cancer cell migration and bone metastases. Cancer Res. 2013;73(15):4852-4861. https://doi.org/10.1158/0008-5472.CAN-12-4572
Stowe DF, Gadicherla AK, Zhou Y, Aldakkak M, Cheng Q, Kwok W-M, et al. Protection against cardiac injury by small Ca2+−sensitive K+ channels identified in Guinea pig cardiac inner mitochondrial membrane. Biochim Biophys Acta. 2013;1828(2):427-442. https://doi.org/10.1016/j.bbamem.2012.08.031
Dolga AM, De Andrade A, Meissner L, Knaus H-G, Höllerhage M, Christophersen P, et al. Subcellular expression and neuroprotective effects of SK channels in human dopaminergic neurons. Cell Death Dis. 2014;5(1):e999. https://doi.org/10.1038/cddis.2013.530
Dolga AM, Netter MF, Perocchi F, Doti N, Meissner L, Tobaben S, et al. Mitochondrial small conductance SK2 channels prevent glutamate-induced Oxytosis and mitochondrial dysfunction. J Biol Chem. 2013;288(15):10792-10804. https://doi.org/10.1074/jbc.M113.453522
Lin MT, Adelman JP, Maylie J. Modulation of endothelial SK3 channel activity by Ca2+−dependent caveolar trafficking. Am J Physiol Cell Physiol. 2012;303(3):C318-C327. https://doi.org/10.1152/ajpcell.00058.2012
Gao Y, Balut CM, Bailey MA, Patino-Lopez G, Shaw S, Devor DC. Recycling of the Ca2+−activated K+ channel, KCa2.3, is dependent upon RME-1, Rab35/EPI64C, and an N-terminal domain. J Biol Chem. 2010;285(23):17938-17953. https://doi.org/10.1074/jbc.M109.086553
Guéguinou M, Gambade A, Félix R, Chantôme A, Fourbon Y, Bougnoux P, et al. Lipid rafts, KCa/ClCa/Ca2+ channel complexes and EGFR signaling: novel targets to reduce tumor development by lipids? Biochim Biophys Acta. 2015;1848(10):2603-2620. https://doi.org/10.1016/j.bbamem.2014.10.036
Juárez-Contreras R, Rosenbaum T, Morales-Lázaro SL. Lysophosphatidic acid and ion channels as molecular mediators of pain. Front Mol Neurosci. 2018;11:462. https://doi.org/10.3389/fnmol.2018.00462
Miller AN, Long SB. Crystal structure of the human two-pore domain potassium channel K2P1. Science. 2012;335(6067):432-436. https://doi.org/10.1126/science.1213274
Jeong KJ, Cho KH, Panupinthu N, Kim H, Kang J, Park CG, et al. EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: inhibition by resveratrol. Mol Oncol. 2013;7(1):121-129. https://doi.org/10.1016/j.molonc.2012.10.001
Romito O, Guéguinou M, Raoul W, Champion O, Robert A, Trebak M, et al. Calcium signaling: a therapeutic target to overcome resistance to therapies in cancer. Cell Calcium. 2022;108:102673. https://doi.org/10.1016/j.ceca.2022.102673
Yu SP. Regulation and critical role of potassium homeostasis in apoptosis. Prog Neurobiol. 2003;70(4):363-386. https://doi.org/10.1016/S0301-0082(03)00090-X
Pillozzi S, D'Amico M, Bartoli G, Gasparoli L, Petroni G, Crociani O, et al. The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome cisplatin resistance in colorectal cancer cells. Br J Cancer. 2018;118(2):200-212. https://doi.org/10.1038/bjc.2017.392
Li H, Yang J, Yang G, Ren J, Meng Y, Qi P, et al. Identification of prognostic alternative splicing events in sarcoma. Sci Rep. 2021;11(1):14949. https://doi.org/10.1038/s41598-021-94485-x
Liu X, Wei L, Zhao B, Cai X, Dong C, Yin F. Low expression of KCNN3 may affect drug resistance in ovarian cancer. Mol Med Rep. 2018;18:1377-1386. https://doi.org/10.3892/mmr.2018.9107